[go: up one dir, main page]

DK1146862T3 - Farmaceutiske sammensætninger - Google Patents

Farmaceutiske sammensætninger

Info

Publication number
DK1146862T3
DK1146862T3 DK99900623T DK99900623T DK1146862T3 DK 1146862 T3 DK1146862 T3 DK 1146862T3 DK 99900623 T DK99900623 T DK 99900623T DK 99900623 T DK99900623 T DK 99900623T DK 1146862 T3 DK1146862 T3 DK 1146862T3
Authority
DK
Denmark
Prior art keywords
gastric
particles
polymer
active ingredient
intestinal juices
Prior art date
Application number
DK99900623T
Other languages
English (en)
Inventor
Gerald Huber
Peter Gruber
Original Assignee
Disphar Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disphar Int Bv filed Critical Disphar Int Bv
Application granted granted Critical
Publication of DK1146862T3 publication Critical patent/DK1146862T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99900623T 1999-01-29 1999-01-29 Farmaceutiske sammensætninger DK1146862T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1999/000180 WO2000044353A1 (de) 1999-01-29 1999-01-29 Pharmazeutische zusammensetzungen

Publications (1)

Publication Number Publication Date
DK1146862T3 true DK1146862T3 (da) 2003-07-21

Family

ID=11004817

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99900623T DK1146862T3 (da) 1999-01-29 1999-01-29 Farmaceutiske sammensætninger

Country Status (15)

Country Link
US (1) US6962717B1 (da)
EP (1) EP1146862B1 (da)
JP (1) JP2002535353A (da)
AT (1) ATE238040T1 (da)
AU (1) AU764469B2 (da)
BR (1) BR9916972B1 (da)
CA (1) CA2360655C (da)
DE (1) DE59905248D1 (da)
DK (1) DK1146862T3 (da)
ES (1) ES2197600T3 (da)
MX (1) MXPA01007463A (da)
NO (1) NO329231B1 (da)
NZ (1) NZ513037A (da)
PT (1) PT1146862E (da)
WO (1) WO2000044353A1 (da)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
PT1190712E (pt) * 2000-09-22 2005-01-31 Smb Technology Composicao de esferas de tramadol para administracao oral uma vez por dia
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AR034813A1 (es) † 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
DE60124895D1 (de) * 2001-07-26 2007-01-11 Ethypharm Sa Umgehüllte Allylamine oder Benzylamine enthaltende Granulate, Verfahren zur Herstellung und in der Mundhöhle dispergierbare Tabletten enthaltend die umgehüllten Granulate
AU2011205217B2 (en) * 2001-08-06 2013-06-13 Euro-Celtique S.A. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
WO2003057195A1 (en) * 2002-01-11 2003-07-17 Athpharma Limited Pravastatin pharmaceutical formulations and methods of their use
JP2006511449A (ja) * 2002-04-29 2006-04-06 シャイア ラボラトリーズ，インコーポレイテッド 改良されたバイオアベイラビリティーを有する薬学的処方物
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
BRPI0413474A (pt) * 2003-08-13 2006-10-17 Smith Howard J & Ass Pty Ltd uso de interferon e ribavirina e kit para uso no tratamento de infecções virais
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
EP1689373B1 (en) * 2003-10-10 2019-04-03 Ethypharm Sustained-release microgranules containing ginkgo biloba extract and the process for manufacturing these
ES2359375T3 (es) * 2003-11-04 2011-05-20 Supernus Pharmaceuticals, Inc. Formas de dosificación de dosis única diaria de trospio.
AU2004289222B2 (en) 2003-11-04 2010-01-21 Supernus Pharmaceuticals Inc. Compositions of quaternary ammonium containing bioavailability enhancers
EP1547601A1 (en) 2003-12-23 2005-06-29 Ferring B.V. Coating method
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US7662802B2 (en) * 2004-09-17 2010-02-16 Gluconova, LLC Halide-free glucosamine-acidic drug complexes
US9205054B2 (en) 2005-03-22 2015-12-08 Losan Pharma Gmbh Solubilized ibuprofen
GR1006875B (el) * 2005-06-30 2010-07-12 "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
PL1915137T3 (pl) * 2005-08-10 2014-03-31 Add Advanced Drug Delivery Tech Ltd Preparat doustny o kontrolowanym uwalnianiu
CN101252932B (zh) 2005-09-09 2012-10-03 安吉利尼莱博法姆有限责任公司 用于一天给药一次的曲唑酮组合物
RU2008113439A (ru) 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2008023027A2 (en) * 2006-08-24 2008-02-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing pramipexole dihydrochloride tablets with high storage stability
EP2063871A1 (en) 2006-08-30 2009-06-03 Jagotec AG Controlled release solid oral dosage formulations comprising nisoldipine
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
CA2704949A1 (en) 2007-11-13 2009-05-22 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090131386A1 (en) 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US9649334B2 (en) 2007-11-15 2017-05-16 The Uab Research Foundation Use of nitrite salts in chronic ischemia
AU2009265099A1 (en) * 2008-07-01 2010-01-07 Lupin Limited Sustained release pharmaceutical compositions comprising Quetiapine
US8945616B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
US20120237617A1 (en) 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
WO2011047161A1 (en) 2009-10-14 2011-04-21 TheraVasc, LLC Pharmaceutical formulations of nitrite and uses thereof
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
EP2340812A1 (en) * 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
US20140112983A1 (en) * 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
US20140328884A1 (en) * 2011-12-16 2014-11-06 Celanese Eva Performance Polymers, Inc. Controlled release vehicles having desired void volume architectures
EA201491477A1 (ru) * 2012-03-02 2015-02-27 Меда Фарма Гмбх Унд Ко. Кг Фармацевтические составы, содержащие флупиртин
MX362838B (es) 2012-07-12 2019-02-19 SpecGx LLC Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
BR112015019802A2 (pt) 2013-02-20 2017-07-18 Theravasc Inc formulações farmacêuticas de nitrito e usos das mesmas
US8652527B1 (en) * 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN104922078B (zh) * 2015-06-23 2018-10-23 上海市计划生育科学研究所 非诺贝特迟释微丸、制备方法及应用
PL3324948T3 (pl) * 2015-07-17 2023-06-26 BE Pharbel Manufacturing Wielowarstwowe mikrocząstki uwalniające związek farmaceutycznie aktywny w płynnej postaci dawkowania
BE1024339B1 (fr) * 2016-07-01 2018-01-29 Be Pharbel Mfg Sa Microparticules multicouches libérant un composé pharmaceutiquement actif dans une forme pharmaceutique liquide
US12472149B2 (en) 2015-07-17 2025-11-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
EP3117824A1 (en) * 2015-07-17 2017-01-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
EP3162362A1 (de) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
ITUA20162293A1 (it) * 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
SG11201811345TA (en) 2016-07-14 2019-01-30 Achaogen Inc Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
WO2018129061A1 (en) * 2017-01-05 2018-07-12 Cormedix Inc. Antimicrobial delivery system for the prevention and treatment of infections in the colon
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
AU2020258086A1 (en) 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
DE3151196A1 (de) 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
DK58983D0 (da) 1983-02-11 1983-02-11 Leo Pharm Prod Ltd Farmaceutisk praeparat
SE457505B (sv) 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
DK62184D0 (da) 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
EP0212745B1 (en) 1985-08-16 1991-04-10 The Procter & Gamble Company Drug particles having constant release
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
AU591248B2 (en) 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
SE9002017D0 (sv) * 1990-06-06 1990-06-06 Kabivitrum Ab Process for manufacture of matrices
JP3286315B2 (ja) 1990-06-20 2002-05-27 アドバンスト ポリマー システムズ，インコーポレイティド 可溶性活性物質の調節された放出のための組成物及び方法
SE9002339L (sv) 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
SE9003296L (sv) 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
GB9025372D0 (en) 1990-11-22 1991-01-09 Nat Res Dev Pharmaceutical dosage forms
GEP19971086B (en) 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
WO1992016214A1 (en) 1991-03-15 1992-10-01 Norwich Eaton Pharmaceuticals Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
JPH07223970A (ja) 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
JP2917799B2 (ja) 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
AU702934B2 (en) 1995-12-21 1999-03-11 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases
WO1997025980A1 (en) * 1996-01-16 1997-07-24 Advanced Polymer Systems, Inc. Topical delivery of drugs to the lower gastrointestinal tract
WO1998020858A1 (en) 1996-11-12 1998-05-22 Pharmacia & Upjohn Ab COMPACT MEMBER COMPRISING A PLURALITY OF POROUS CELLULOSE MATRICES, (PCMs), METHOD OF MANUFACTURING AND USE THEREOF

Also Published As

Publication number Publication date
MXPA01007463A (es) 2002-06-04
NO20013336D0 (no) 2001-07-05
AU1980899A (en) 2000-08-18
EP1146862B1 (de) 2003-04-23
WO2000044353A1 (de) 2000-08-03
ES2197600T3 (es) 2004-01-01
PT1146862E (pt) 2003-09-30
CA2360655C (en) 2007-03-20
EP1146862A1 (de) 2001-10-24
NO329231B1 (no) 2010-09-20
NO20013336L (no) 2001-09-25
BR9916972A (pt) 2001-11-06
NZ513037A (en) 2003-05-30
CA2360655A1 (en) 2000-08-03
US6962717B1 (en) 2005-11-08
BR9916972B1 (pt) 2010-05-18
AU764469B2 (en) 2003-08-21
DE59905248D1 (de) 2003-05-28
ATE238040T1 (de) 2003-05-15
JP2002535353A (ja) 2002-10-22

Similar Documents

Publication Publication Date Title
DK1146862T3 (da) Farmaceutiske sammensætninger
EP2277510A3 (en) Controlled release preparation
CA2264238A1 (fr) Forme galenique a liberation prolongee de milnacipran
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
CA2037101A1 (en) Omeprazole Compositions Designed for Administration in Rectum
WO2008149440A1 (ja) 速溶性及び可撓性を有するフィルム製剤
EP0390541A3 (en) Paste-like base and preparation
EP1690530A3 (en) Sustained release pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
DK0868910T3 (da) Anvendelse af redispergerbare polymerpulvere eller polymergranulater som bindemidler til fremstilling af faste farmaceutiske dispergeringsformer
CA2376226A1 (en) New formulation
GEP20053448B (en) Antibiotic and Polymeric Composition
CA2409828A1 (en) Formulation based in heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
ATE425744T1 (de) Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit
NZ709754A (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2004060405A8 (en) Tissue reactive compounds and compositions and uses thereof
RU2008136408A (ru) Фармацевтическая композиция
ATE482689T1 (de) Blockcopolymer-mizellenzusammensetzung mit verbesserter arzneimittelbeladungskapazität und verzögerter freisetzung
EP2311871A3 (en) IL-1 antagonist stable liquid formulation
DE59909717D1 (de) Verfahren zur Herstellung von festen Dosierungsformen
MX2025001734A (es) Formas farmacéuticas sólidas orales que contienen cannabinoides
TW200624464A (en) Amphiphilic block copolymer and pharmaceutical formulation comprising the same
ATE234608T1 (de) Mikrokapseln mit verzögerter freisetzung von wirkstoffen
CA2473718A1 (en) Immediate-release pharmaceutical dosage form comprising polymorphous tibolone
EA200401145A1 (ru) Оральная фармацевтическая композиция с модифицированным высвобождением